Compare ACADIA Pharmaceuticals Inc. (ACAD) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs McDonald's Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while McDonald's Corp trades at $275.87 (market cap $194.00B). The key difference: McDonald's Corp is far larger — about 38.3× ACADIA Pharmaceuticals Inc.'s market cap, and McDonald's Corp pays a 2.71% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MCD | |
|---|---|---|
Market Cap | $5.07B | $194.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $341.06 |
52-Week Low | $20.06 | $262.80 |
Enterprise Value | $4.19B | $247.77B |
Volume | — | 2,230,036 |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.
McDonald's (MCD) trades at $273.72, down 0.28% on the day, with a neutral technical signal and strong fundamentals including a 31.72% net margin and consistent earnings beats. The company recently unveiled its 'McDonald's NEXT' growth strategy focusing on automation and menu innovation to drive future performance. Revenue growth remains steady, with 2025 revenue at $26.89 billion.
Outlook is positive with a consensus price target of $322.45 offering 17.8% upside, supported by 60% analyst buy ratings. Risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. The stock presents a value opportunity with stable dividends and strategic initiatives aimed at enhancing competitiveness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
